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Abstract 
In recent years, new anticancer therapies have accompanied the classical approaches of 
surgery and radio- and chemotherapy. T h e s e   n e w   f o r m s   o f   t r e a t m e n t   a i m   t o   i n h i b i t   s p e c i f i c  
molecular targets namely altered or deregulated proteins, which offer the possibility of indi-
vidualized therapies.  
The specificity and efficiency of these new approaches, however, bring about a number of 
challenges. First of all, it is essential to specifically identify and quantify protein targets in tumor 
t i s s u e s   f o r   t h e   r e a s o n a b l e   u s e   o f   s u c h   t a r g e t e d   t h e r a p i e s .   A d d i t i o n a l l y ,   i t   h a s   b e c o m e   e v e n  
more obvious in recent years that the presence of a target protein is not always sufficient to 
predict the outcome of targeted therapies. The deregulation of downstream signaling mo-
lecules might also play an important role in the success of such therapeutic approaches. For 
these reasons, the analysis of tumor-specific protein expression profiles prior to therapy has 
been suggested as the most effective way to predict possible therapeutic results. To further 
elucidate signaling networks underlying cancer development and to identify new targets, it is 
necessary to implement tools that allow the rapid, precise, inexpensive and simultaneous 
analysis of many network components while requiring only a small amount of clinical material.  
Reverse phase protein microarray (RPPA) is a promising technology that meets these re-
quirements while enabling the quantitative measurement of proteins. Together with recently 
developed protocols for the extraction of proteins from formalin-fixed, paraffin-embedded 
(FFPE) tissues, RPPA may provide the means to quantify therapeutic targets and diagnostic 
markers in the near future and reliably screen for new protein targets. 
With the possibility to quantitatively analyze DNA, RNA and protein from a single FFPE tissue 
sample, the methods are available for integrated patient profiling at all levels of gene ex-
pression, thus allowing optimal patient stratification for individualized therapies. 
Key words: Formalin-fixed, paraffin-embedded (FFPE); human epidermal growth factor receptor 2 
(HER2); epidermal growth factor receptor 1 (EGFR); urokinase-type plasminogen activator (uPA); 
plasminogen activator inhibitor 1 (PAI-1); personalized cancer therapy; mitogen-activated protein 
kinase (MAPK) 
Introduction 
The  deregulation of signaling pathways in tu-
mors can lead to enhanced cancer cell growth, proli-
feration, survival, invasion, and metastasis or reduced 
apoptosis [1, 2].   S u c h   p a t h w a y s   b e c a m e   t h e   f o c u s   o f  
the development of targeted cancer therapies during 
the last decades [3-5]. Kinases are of special interest 
within these systems, either as receptor molecules or 
downstream regulators of signaling cascades (see Ta-
ble 1 for an overview of targeted therapies). Examples 
o f   r e c e p t o r   k i n a s e s   t o   b e   f u r t h e r   d i s c u s s e d   i n   t h i s   r e-Journal of Cancer 2011, 2 
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view are the human epidermal growth factor recep-
t o r s   1   ( E G F R )   a n d   2   ( H E R 2 ) .   B o t h   k i n a s e s   a r e   t a r g e t s  
for anticancer drugs and can be analyzed for their 
expression by clinically approved tests, such as im-
munohistochemistry  (IHC)  and  fluorescence  in  situ 
h y b r i d i z a t i o n   ( F I S H ) .   E G F R   o v e r e x p r e s s i o n   d u e   t o  
gene amplification is often found in human cancers; in 
gliomas,  this  deregulation  is  often  associated  with 
structural rearrangements leading  to  in-frame  dele-
t i o n s   i n   t h e   e x t r a c e l l u l a r   d o m a i n   o f   t h e   r e c e p t o r   [6]. 
H E R 2   o v e r e x p r e s s i o n   a s   f o u n d   i n   2 5   t o   3 0 %   o f   h u m a n  
b r e a s t   c a n c e r s   c a n   b e   m e d i a t e d   e i t h e r   b y   t r a n s c r i p-
tional  activation  or  gene  amplification  [7-10].  The 
H E R 2   s t a t u s   o f   b r e a s t   c a n c e r   p a t i e n t s   d o e s   n o t   o n ly 
have a predictive value, but the receptor itself is also a 
target  for  the  monoclonal  anti-HER2  antibody  Tras-
tuzumab [8]. Recent evidence has demonstrated that 
besides  being  an  important  therapeutic  target  in 
b r e a s t   c a n c e r ,   H E R 2   i s   a   t a r g e t   f o r   t h e   t r e a t m e n t   o f  
metastasized  gastric  cancers  [11,  12],  and  thus,  the 
anticancer  drug  Herceptin  (Trastuzumab)  was  ap-
p r o v e d   f o r   t h e   t r e a t m e n t   o f   a d v a n c e d   g a s t r i c   c a r c i-
n o m a s .   H E R 2   i s   c u r r e n t l y   d e t e c t e d   b y   i m m u n o h i s t o-
chemistry  (IHC)  and  fluorescence  in  situ  hybridiza-
t i o n   ( F I S H ) ,   a n d   p r o t o c o l s   f o r   t h e   d e t e c t i o n   o f   H E R 2   i n  
gastric  cancers  by  IHC  were  recently  suggested  by 
Rüschoff  et  al.  [13].   H o w e v e r ,   a l t h o u g h   H E R 2   i s  
well-established  as  a  therapeutic  target,  recent  evi-
dence suggests that down-stream signaling molecules 
m a y   b e   b e t t e r   p r e d i c t o r s   f o r   a   r e s p o n s e   t o   a   H E R 2  
directed therapy than the receptor itself. This follows 
from  the  fact  that  the  membrane-bound  molecule 
a l o n e   d o e s   n o t   n e c e s s a r i l y   l e a d   t o   a n   a c t i v a t i o n   o f   t h e  
signaling  cascade.  For  that  reason,  identifying  the 
activation status of cancer-related signaling cascades 
might  provide  a  better insight  into  the  mechanisms 
underlying the success and failure of targeted thera-
pies, thus providing a useful approach to stratify pa-
tients for optimal personalized treatment regimens. 
To individualize cancer, biomarker identification 
h a s   b e c o m e   e v e n   m o r e   i m p o r t a n t   f o r   t h e   s t r a t i f i c a t i o n  
of  patients  for  special  treatment  regimens.  Uroki-
nase-type plasminogen activator (uPA) and its inhi-
bitor  plasminogen  activator  inhibitor-1  (PAI-1)  are 
p r o m i n e n t   e x a m p l e s   o f   s u c h   b i o m a r k e r s .   B o th  are 
used to provide a more detailed prognosis for nod-
al-negative breast cancer patients and have reached 
t h e   h i g h e s t   l e v e l   o f   e v i d e n c e   ( L O E   I )   f o r   t h i s   p u r p o s e  
[14].
 
Table 1: Drugs currently used for targeted therapy 
Drug  Tumor type  Target  Detection method 
Trastuzumab [3]  Metastatic breast cancer, 
gastric cancer 
HER2  IHC, FISH, ISH 
Cetuximab [3]  Metastatic colorectal cancer  EGFR  IHC, FISH 
Imatinib Mesylate 
(Gleevec) [3] 
CML, GIST with activated c-kit receptor tyrosine 
kinase, other sarcomas 
Bcr/abl, c-kit, PDGFR,   IHC 
Bevacizumab [3]  Colorectal cancer  VEGF  IHC 
Gefitinib (Iressa)  Non-small-cell lung cancer  mutant EGFR  Mutational analysis, immu-
noblotting 
G3139 (Genta, Berkley) [3]  Hematologic malignancies and malignant mela-
noma 
Antiapoptotic gene bcl-2   Immunophenotyping by IHC 
Erlotinib (Tarveca) [3]  Non-small-cell lung cancer  mutant EGFR  Mutational analysis, immu-
noblotting 
Rapamycin RAD001 [3]  Breast, prostate, renal cancer  mTOR  ELISA 
BAY43-9006 [3]  Melanoma  RAF kinase  Mutational analysis 
BMS354825 [3]  GIST  Kit  IHC 
Lapatinib [5]  Breast cancer  EGFR, HER2  IHC, FISH, ISH 
Sunitinib [5]  Renal cell cancer  VEGFR, PDGFR, cKit, Flt-3  IHC 
Pertuzumab [4]  Breast cancer  HER2  IHC, FISH, ISH 
Dasatinib [4]  Breast cancer  Bcr/abl  RT-PCR 
Abbreviations: HER2 (human epidermal growth factor receptor 2); EGFR (epidermal growth factor receptor); c-abl (Abelson Murine Leu-
kemia Viral Oncogene Homolog 1); bcr (breakpoint cluster region); Bcr/abl (fusion gene of bcr and abl in Philadelphia Chromosomes); c-kit 
(s t e m   c e l l   f a c t o r -receptor); PDGFR (platelet-derived growth factor receptor); VEGF (vascular endothelial growth factor receptor); bcl-2 (B-cell 
lymphoma 2); TOR (target of rapamycin); RAF (rapidly growing fibrosarcoma); Flt-3 (fms-like tyrosine kinase receptor-3); IHC (immuno-
histochemistry); FISH (fluorescence in situ hybridization); ISH (in situ hybridization) Journal of Cancer 2011, 2 
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H o w e v e r   t h e   l e v e l   o f   t h e s e   t w o   m a r k e r s   c a n   j u s t  
be determined in fresh-frozen tissue. This is proble-
matic  as  formalin-fixed,  paraffin-embedded  (FFPE) 
tissue  is  the  main  source  of  patient  material  world 
wide. Therefore for clinical determination of diagnos-
tic and therapeutic targets new methods are crucially 
needed to maximize the data that can be gleaned from 
t h i s   k i n d   o f   t i s s u e .   T h e   r e c e n t l y   d e v e l o p e d   m e t h o d   t o  
extract  full-length,  immunoreactive  proteins  from 
FFPE tissues (for review see [15]) is a major progress 
for such approaches and provides the means to quan-
titate clinically relevant proteins like HER2 and ana-
lyze cancer-r e l a t e d   p a t h w a y s   b y   r e v e r s e   p h a s e   p r o t e i n  
microarray (RPPA)[16]. 
Because the field of targeted therapy is growing 
rapidly, it is important to emphasize the necessity of 
standardization for pre-analytical as well as analytical 
settings.  
In this review, we shed light on new develop-
ments for the detection of therapeutic protein targets 
and  diagnostic  biomarkers  in  clinical  tissues  and 
comment  on  suggestions  for  the  standardization  of 
tissue handling and analysis. 
Proteomics of formalin-fixed, paraf-
fin-embedded tissues  
Formalin is the standard fixative in clinical tissue 
collections  worldwide  and  the  method  of  formalin 
fixation was described in detail in a previous article of 
the  authors  [17].  The  protein  and  nucleic  acid 
cross-linking induced by formalin maintains the tis-
s u e   i n   a n   e x c e l l e n t   c o n d i t i o n   f o r   t h e   p a t h o l o g i c a l   e x-
amination  of  the  morphological  characteristics  of 
diseased  tissues  [18].   W i t h   t h e   n e w   i n t e r e s t   i n   m a-
cromolecules  (DNA,  RNA,  proteins)  as  therapeutic 
targets  or  biomarkers,  scientists  began  to  analyze 
these  entities  first  in  frozen  material  because  FFPE 
f i x a t i o n   r e q u i r e d   t o   p r e s e r v e   t h e   t i s s u e   m o r p h o l o g y  
had  adverse  effects  on  macromolecules,  especially 
p r o t e i n s .   B y   a d o p t i o n   o f   a n t i g e n   r e t r i e v a l   f i r s t   d e-
scribed by Ikeda et al. [19] i t   w a s   p o s s i b l e   t o   d e v e l o p  
an assembly of protocols enabling extraction of pro-
teins from FFPE tissues [18-26].   A n   o v e r v i e w   o f   t h e s e  
methods is provided in a recent review by Berg et al., 
2010  [15].   C o m p a r e d   t o   o t h e r   r e c e n t   s t u d i e s   [27-30], 
using these protocols non-degraded, full-length, and 
immunoreactive proteins are obtained and may then 
b e   u s e d   f o r   p r o t e i n   p r o f i l i n g   f o r   e n h a n c e d   d i a g n o s i s .  
H o w e v e r   o n e   s h o u l d   k e e p   i n   m i n d   t h a t   a l l   p r o t o c o l s  
require  high  SDS  concentrations,  temperature  and 
pH, which is problematic for some down-stream  ap-
plications such as ELISA assays. To assure the integr-
ity of isolated proteins we always do a quantification 
of  the  total  protein  obtained  by  extraction  (Brad-
ford-Assay) and additionally check for correct protein 
m a s s e s   b y   c o n t r o l   w e s t e r n   b l o t s .   O t h e r   a u t h o r s   s u g-
g e s t   c o n t r o l l i n g   f o r   p r o t e i n   i n t e g r i t y   b y   M S   [26, 31-33]. 
I n   t h e   s c o p e   o f   t u m o r   m a r k e r   r e s e a r c h   a n d   p e r s o n a l-
ized medicine further aspects of investigation became 
of major interest: pre-analytical workflow and tissue 
quality. For molecular diagnostics protein biomarkers 
need to be precisely measured in high-quality tissue 
s a m p l e s .   I t   i s   k n o w n   t h a t   specimens  undergo  nu-
merous processing steps from the collection of patient 
samples to the final diagnostic analysis. This aspect of 
t h e   s a m p l e   h i s t o r y   i s   v e r y   i m p o r t a n t   w i t h   r e g a r d   t o  
the identification of disease-related  biomarkers.  But 
so far there were no detailed investigations concern-
ing for example the influence of temperature and time 
during transportation, fixation method and storage on 
t h e   m o l e c u l a r   i n t e g r i t y   o f   t i s s u e   s a m p l e s .   I n   o r d e r   o f  
r e p r o d u c i b i l i t y   o f   s u b s e q u e n t   d i a g n o s i s   t h e   i m p a c t   o f  
pre-analytical  parameters  on  biomolecular  integrity 
and expression needs to be analyzed in detail. Fur-
thermore  we  need  guidelines  for  the  standardized 
collection, handling, stabilization and storage of bio-
samples and quality assurance indicators for artificial, 
post  collection  changes  of  biological  samples.  Two 
large international initiatives are working toward this 
g o a l ,   o n e   f u n d e d   b y   t h e   E U   ( w w w . s pidia.eu) and one 
b y   t h e   U S   ( http://biospecimens.cancer.gov). In Table 
2   w e   h i g h l i g h t   t h e   m o st important problems occurring 
during  the  pre-analytical phase of sample prepara-
tion. 
Table 2: Pre-analytical parameters influencing the quality of biological samples and hindering the quantitative analysis of 
potential biomarkers and drug targets 
Pre-analytical parameters  Source of errors  Proposed solutions 
Medication before surgery and type of anaesthesia  Influence on gene or protein ex-
pression 
Detailed documentation and account for it during 
analysis  
Time of vessel ligation  Time is unknown   Detailed documentation 
Time of specimen removal  Time is unknown   Detailed documentation 
L o c a t i o n   o f   s p e c i m e n   r e m o v a l   ( e . g .   c e n t r e   o f   a   t u m o u r  
or periphery) 
Tumour area not homogeneous  Comparison only between homogeneous pieces, 
detailed documentation 
Time and temperature of transport e.g. to pathology  Time and conditions are unknown  As fast as possible, detailed documentation 
Time until fixation  Time is unknown   As fast as possible, detailed documentation 
Type and duration of fixation  Cross-linking by formalin   Novel fixation methods 
Temperature and duration of fixation  Not standardized  Standardized conditions, detailed documentation 
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T h e s e   d i f f i c u l t i e s   a r e   a l s o   t h e   m a i n   f o c u s   o f   t h e  
projects mentioned above. The issue of the evaluation 
of adverse and variable effects of sample preparation 
i s   d i s c u s s e d   i n   m o r e   d e t a i l   i n   a   r e c e n t   r e v i e w   b y  
Becker and Taylor [34]. 
Reverse Phase Protein Microarrays 
Although  morphological  parameters,  namely 
tumor size, grade and staging, are the most important 
p a r a m e t e r s   f o r   d i a g n o s i s ,   t h e y   d o   n o t   a d d r e s s   t h e  
complexity and heterogeneity of individual tumors at 
the molecular level [35, 36]. However, since individu-
a l i z e d   c a n c e r   t h e r a p i e s   a r e   o n   g a i n i n g   g r o u n d   m o r e  
detailed patient classifications are necessary to be able 
t o   i d e n t i f y   t h e   r i g h t   t h e r a p y   f o r   e a c h   p a t i e n t .   O n e  
widely  accepted  approach  is  the  gene  microarray. 
Anyway, it is important to realize that transcript pro-
f i l i n g   d o e s   n o t   a c c u r a t e l y   r e f l e c t   t h e   c o m p l e x i t y   o f  
cellular  protein  networks  (e.g.  protein-protein  inte-
ractions,  protein  localization  or  posttranslational 
modifications)  [37].  Additionally,  several  groups 
demonstrated that there is no constrained correlation 
between gene transcript levels and protein expression 
or the functional state of a protein. [38-41].  
H o w e v e r   e s p e c i a l l y   t h e   c o m m u n i c a t i o n   i n   s u c h   a  
protein network, which is responsible for activation 
and deactivation of involved proteins, is often altered 
in cancer and may then lead to aberrant cellular func-
tions  that  result in  proliferation, apoptosis, differen-
tiation, survival, invasion and metastasis. That’s why 
it  is  of  great  importance n o t   o n l y   t o   l o o k   a t   t h e   e x-
pressi o n   o f   g e n e s   o r   a t   t h e   a c t i v a t i o n   s t a t e   o f   a   s i n g l e  
protein  but  to  analyze  whole  protein  signaling  net-
works that then can provide fundamental information 
about the functional state of signaling pathways [42, 
43].   O n e   m e t h o d   w h i c h   m e e t s   a l l   d e m a n d s   f o r   s u c h   a  
n e t w o r k   m o n i t o r i n g   i s   t h e   r e v e r s e   p h a s e   p r o t e i n   m i-
croarray (RPPA). This array format allows the simul-
t a n e o u s   a n a l y s i s   o f   m u l t i p l e   s a m p l e s   f o r   t h e   e x p r e s-
sion of several proteins under the same experimental 
c o n d i t i o n s   e v e n   f r o m   s m a l l   n u m b e r s   o f   t u m o r   c e l l s   o r  
small specimens such as biopsies [44,  45].  Like  this 
changes in protein expression levels or phosphoryla-
tion states, before and after treatment, between dis-
ease and non-disease states and between responders 
and non-responders can be monitored [35].   T h e   p r o-
c e d u r e   t o   g e n e r a t e   s u c h   a n   a r r a y   i s   s i m p l e .   A f t e r   p r o-
tein  extraction  from any kind of material (e.g. cells, 
FFPE  tissue  or  fresh-frozen material), each sample is 
arrayed  in  triplicate  on  nitrocellulose-coated  slides 
u s i n g   s e v e r a l   d i l u t i o n s   t o   e n s u r e   t h a t   e a c h   a n a-
lyte/antibody  combination  can  be  analyzed  in  the 
linear dynamic  range.  After  the  spotting  each  slide 
may be detected with an antibody against the desired 
p r o t e i n   ( f o r   a n   o v e r v i e w   o f   t h e   R P P A   m e t h o d o l o g y ,  
s e e   F i g u r e   1 ) .   H o w e v e r   o n e   s h o u l d   k e e p   i n   m i n d   t h a t  
for a successful implementation of RPPA highly spe-
cific antibodi e s   a r e   n e e d e d   a s   o n e   c a n ’ t   d i s t i n g u i s h  
between different molecular weights (as e.g. in west-
e r n   b l o t )   b u t   o n l y   o n e   s i g n a l   i s   o b t a i n e d .   E s p e c i a l l y   f o r  
phosphorylated proteins and other posttranslational-
l y   m o d i f i e d   p r o t e i n s   t h i s   s e e m s   t o   b e   o n e   o f   t h e   m a j o r  
limiting factors [35, 46]. 
Another advantage of the RPPA is the possibility 
to quantify the total amount of protein in the sample 
via the application of purified recombinant proteins 
one the same slide [15,  16].   T h i s   m e t h o d   e n a b l e s   t o  
measure protein expression from FFPE tissues more 
p r e c i s e l y   t h a n   i t   i s   p o s s i b l e   b y   I H C   ( e . g . ,   f o r   H E R 2 )  
and implement the analysis of clinical markers, which 
until now were only measurable from fresh or frozen 
tissues (e.g. for uPA/PAI-1). This highly quantitative 
approach is advantageous for patient selection; how-
ever, the correlation between protein abundance and 
histology, as provided by IHC, is lost.  
Nevertheless, we successfully established a set of 
about  50  antibodies  for  use  in  RPPA  analysis  by 
stringently selecting for specificity and sensitivity by 
western blot [15, 16] thus providing a starting point 
f o r   t h e   a n a l y s i s   o f   m a j o r   c a n c e r -related  signaling 
p a t h w a y s   f r o m   F F P E   t i s s u e s   o f   c a n c e r   p a t i e n t s .   B a s e d  
on this expertise we recently developed an algorithm 
to validate antibodies for their simultaneous applica-
t i o n   t o   e x t r a c t   b a s e d   a n d   c l a s s i c a l   m o r p h o l o g y   b a s e d  
m e t h o d s   ( S c h u s t e r   C ,   M a l i n o w s k y   K   et al., in prepa-
ration).  With  this  proposal  we  plan  to  combine  the 
advantages of both approaches to get broad insight 
into all aspects of cancer formation and development. 
For the application of RPPA generated data for 
such a purpose in clinical routine it is necessary to be 
able  to  compare  the  results  of  arrays  generated  in 
different hospitals and experimental settings. This can 
be  achieved  by  reference  samples  on  each  slide,  to 
which the signal may be normalized to. Such a control 
h a s   t o   b e   r e n e w a b l e ,   r e p r o d ucible in large-scale, suc-
c e s s f u l   o v e r   a   b r o a d   r a n g e   o f   e n d   p o i n t s ,   s t a b l e   o v e r   a  
l o n g   p e r i o d   o f   t i m e   a n d   a s   c l o s e l y   r e l a t e d   t o   t h e   t e s t  
sample as possible [47]. 
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Figure 1: The principle of reverse phase protein microarrays (RPPA): A: Protein lysates are spotted onto ni-
trocellulose-coated glass slides. Single proteins (e.g., PAI-1) can be detected by an antibody assay similar to a western blot 
analysis; a specific primary antibody binds to the spotted protein. After binding of an enzyme-coupled secondary antibody, 
protein expression can be measured by light- or fluorescence-based as well as colorimetric methods. B: Each sample is 
spotted in triplicate and in a six-step dilution series to ensure the quantitative measurement of the target protein in the linear 
detection range. The normalization of every antibody detected on the slide is performed using a total protein-stained slide 
(e.g., Sypro-Ruby protein stain). 
 
T o   v a l i d a t e   t h e   r e p r o d u c i b i l i t y   o f   t h e   m e t h o d ,   w e  
performed experiments analyzing   t h e   v a r i a b i l i t y   b e-
tween sample preparations, array slides and experi-
mental  setups  (inter-sample  as  well  as  inter-assay 
c o m p a r i s o n s )   a n d   f o u n d   t h e   m e t h o d   t o   b e   h i g h l y   r e-
liable [15]. 
I n   c o m p a r i s o n   t o   t h e   w i d e l y   u s e d   E L I S A  ap-
p r o a c h e s   R P P A s   a r e   m o r e   s e n s i t i v e   a n d   a   t w o -site 
antibody sandwich method is not used, hence there 
won’t be any experimental variability introduced due 
to labeling yield (or) epitope masking. 
Deciphering signaling pathways in clinical 
tissues for personalized medicine  
R P P A s   c a n   b e   i m p l e m e n t e d   i n   n e a r l y   a l l   a r e a s  
regarding the field of personalized medicine. They are 
used for the rapid and comprehensive analysis of new 
d r u g   c a n d i d a t e s   f o u n d   b y   in silico approaches or by 
binding screens for their biological  functions  [48-50], 
as well as for biomarker screenings [51]. 
Many  recent  studies  have  demonstrated  that 
RPPA technology is a v e r y   p r o m i s i n g   t o o l   f o r   s i g n a l-
ing pathway profiling of human tissues and cell lines 
to produce valuable information for the development 
of new therapeutics or patient selection. Feinberg e t   a l .  
was the first to utilize a microspot technique to detect 
antigens in serum [52]. In 2001, another study used 
RPPAs to show the activation of pro-survival proteins 
and  pathways  during  prostate  cancer  progression 
[45]. In our group, we provided insight into the role of 
uPA/PAI-1   i n   c a n c e r   r e l a t e d   s i g n a l i n g   [16].  Other 
prominent examples of cancer-specific signaling de-
regulation namely the activation of the phosphatidy-
linositol  3-kinase  (PI3K)  pathway  in  a  significant 
n u m b e r   o f   o v a r i a n   a n d   c o l o n   t u m o r s   [53,  54].and, 
alterations  in  the  mitogen-activated  protein  kinase 
( M A P K )   p a t h w a y   o r   t h e   o v e r e x p r e s s i o n   o f   H E R 2 , [8, 
53-57] were summarized in an earlier review by the 
authors [17]. These examples demonstrate the diverse 
signaling-based  mechanisms  underlying  cancer  pro-
gression  and  indicate  that  cancer  types (e.g., breast 
c a n c e r )   c a n   b e   s u b d i v i d e d   e . g . ,   i n t o   s m a l l ,  
well-defined subgroups that express a typical protein 
profile. Some authors go even further, suggesting that 
t h e   u s e   o f   a   t a r g e t e d   t h e r a p y   s h o u l d   n o t   b e   b a s e d   o n  
t h e   i d e n t i t y   o f   t h e   c a n c e r   b u t   r ather on the deregula-
tion  of  a  certain  pathway  [58].  Such  an  approach 
would challenge the design of future clinical studies Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
31 
and the approval of new drugs for targeted therapy 
but  could  be  beneficial  for  patients  by  providing 
highly  specific  therapies  that  are  only  based  on  the 
availability of specific targets regardless of the clas-
sical characterization of the cancer type. Such a spe-
cific treatm e n t   c o u l d   g r e a t l y   i n c r e a s e   t h e   q u a l i t y   o f   l i f e  
for  patients  by  minimizing  adverse  side  effects  of 
cancer treatment. 
In  addition  to  classical  biomarker  screenings 
R P P A   i s   a l s o   a n   a d e q u a t e   t o o l   t o   c o m p a r e   d i f f e r e n t  
t y p e s   o f   s a m p l e s   r e g a r d i n g   t h e i r   p r o t e i n   e xpression 
profiles.  One  prominent  example  is  the  expression 
analysis of HER2 from resected tumors versus core 
needle biopsies. Currently, core biopsies are routinely 
u s e d   f o r   d i a g n o s i s   o f   b r e a s t   c a n c e r   a n d   t h e y   a r e   o f t e n  
the only sample for providing prognostic and predic-
tive  markers  before  treatment.  However,  biopsies 
may not accurately reflect protein expression profiles 
f r o m   t h e   w h o l e   t u m o r .   A f t e r   e x t r a c t i o n   o f   f u l l -length 
proteins from FFPE tissues, Berg et al.   u s e d   R P P A s   t o  
compare  HER2,  estrogen  receptor  (ERalpha),  and 
progesterone  receptor  (PGR)  expression  levels  in  a 
s e r i e s   o f   3 5   F F P E   b r e a s t   c a n c e r   s u r g i c a l   s p e c i m e n s   a n d  
their corresponding core biopsies. We found a high 
concordance between  protein expression  in  core  bi-
opsies and surgical specimens. In this study, the au-
t h o r s   c o u l d   s h o w   t h a t   H E R 2 ,   E R a l p h a ,   a n d   P G R   e x-
pression can be assessed reliably on core biopsies of 
FFPE breast cancer tissues using RRPA. These results 
might further strengthen the implementation of RPPA 
technology in routine clinical settings (Berg et al. Pro-
tein microarray-based comparison of HER2, estrogen 
receptor and progesterone receptor status in core bi-
o p s i e s   a n d   s u r g i c a l   s p e c i m e n s   f r o m   F F P E   b r e a s t   c a n-
cer tissues. Appl Immunohistochem Mol Morphol., in 
press 2011). 
Our vision: Combined protein and RNA pro-
filing of cancer tissue from the same sample 
Gene expression profiles (e.g., genes regulating 
c e l l   c y c l e ,   i n v a s i o n   o r   m e t a s t a s i s )   h a v e   b e e n   p r o p o s e d  
as potential biomarkers for the prognosis, prediction 
of treatment response and the identification of poten-
tially  new  drugs  [59].  In  addition  to  the 
well-established  mRNA  profiling,  the  analysis  of 
small non-c o d i n g   R N A s   c a l l e d   m i R N A s   h a s   b e c o m e   a  
focus in biomarker research. In recent years, evidence 
h a s   s u g g e s t e d   t h a t   w h o l e   g r o u p s   o r   f a m i l i e s   o f  
miRNAs are deregulated in different diseases, espe-
cially cancer [60, 61]. 
The quantitative analysis of protein expression 
described in this review may enable the parallel iden-
tification of protein and RNA profiles (mRNA and 
miRNA) using only one FFPE tissue sample. With this 
method,  it  is  possible  to  simultaneously  determine 
mutations in critical genes and relate them to expres-
sion profiles. Gene mutations frequently lead to a loss 
of  gene  function,  although  the  mutated  gene  is  still 
expressed at the RNA and protein levels. A classical 
ex a m p l e   f o r   s u c h   a   m u t a t i o n   i s   t h e   c e l l   a d h e s i o n   m o-
lecule E-c a d h e r i n ,   i n   w h i c h   a   l o s s   o f   E -cadherin func-
t i o n   i s   f o u n d   i n   m a n y   d i f f u s e -type  gastric  cancers, 
although  the  protein  is  expressed  at  high  levels  in 
these  tumors  [62]. Another  useful application  of  the 
combined DNA and protein analysis is the utilization 
of EGFR as a therapeutic target; although EGFR ex-
pression  is  detectable  on  a  protein  level,  many  pa-
t i e n t s   w i t h   c o l o r e c t a l   c a n c e r s   d o   n o t   r e s p o n d   t o   C e-
tuximab  therapy  [63-65].  The  downstream  target  of 
E G F R   i s   m u t a t e d   i n   m a n y   o f   t h e   n o n -responders, 
therefore  blocking  the  EGFR  does  not  inhibit  proli-
ferative signaling. Therefore, the parallel assessment 
of the level of EGFR protein and the mutational status 
o f   t h e   E G F R   g e n e   i s   o n e   i m p o r t a n t   p r e r e q u i s i t e   f o r  
successful Cetuximab treatment [63-65]. The remain-
ing  EGFR-positive  patients  express  the  wild-type 
f o r m   o f   t h e   p r o t e i n   a n d   p r o v i d e   a   g o o d   e x a m p l e   f o r  
the need of additional biomarkers for the prediction of 
therapeutic response. Many of these patients do not 
respond to   C e t u x i m a b   t h e r a p y ,   p r o b a b l y   d u e   t o   f u r-
t h e r   a l t e r a t i o n s   i n   p a t h w a y s   d o w n s t r e a m   o f   E G F R .   I n  
recent years, several additional candidate biomarkers 
of EGFR resistance were suggested. Molecular aber-
rations occur in BRAF, PIK3CA and PTEN, which are 
known  downst r e a m   e f f e c t o r s   o f   E G F R   [66-69].  So-
m a t i c   m u t a t i o n s   i n   t h e s e   E G F R   e f f e c t o r s   c o r r e l a t e  
w i t h   t h e   r e d u c e d   e f f i c a c y   o f   C e t u x i m a b   i n   p a t i e n t s  
with  metastatic  colorectal  cancers  [70,  71].  An  acti-
v a t i n g   m u t a t i o n   o f   B R A F ,   w h i c h   l i e s   d o w n s t r e a m   o f  
t h e   E G F R   s i g n a l i n g   c a s c a d e ,   w a s   f o u n d   i n   a   p r o p o r-
tion of patients with wild-type E G F R   t h a t   d o   n o t   r e-
spond to Cetuximab treatment [66]. For that reason, 
BRAF mutational analysis is currently recommended 
by  the  National  Comprehensive  Cancer  Network 
(NCCN)  clinical  guidelines  for  patients  with  “wild 
type”  metastatic  or  recurrent  colorectal  cancers  that 
are receiving Cetuximab [72].  
Recently, we succeeded in the parallel extraction 
of  proteins  and  RNA,  including  miRNA,   f r o m   t h e  
same FFPE tissue sample (Malinowsky et al.;  unpub-
lished data), demonstrating the proof of principle of 
our vision. While FFPE samples are a large challenge 
of the clinical application of the combined analysis of 
protein  and  RNA,  new  formalin-free  fixatives,  e.g. 
PAXgene  tissue  fixation  and  stabilization  reagents 
[73],  HOPE  [74-76],  RCL2  [77-79],  Finefix  [80], 
metacarn [81] or  Umfix  [82] show great  potential  to 
serve  as  novel  multimodal  fixatives  for  modern Journal of Cancer 2011, 2 
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pathology,  enabling  extensive  protein  biomarker 
studies on clinical tissue samples. Regardless of the 
n a t u r e   o f   t h e   f i x a t i v e ,   o u r   a p p r o a c h   a l l o w s   t h e   i n t e-
gration of analysis at all three levels of gene expres-
sion (DNA, RNA and protein), providing insight into 
the whole spectrum of potential biomarkers (Figure 
2). 
 
 
Figure 2: The integration of DNA, RNA and protein profiling into a routine clinical workflow: The parallel 
analysis of the morphology as well as DNA, RNA and protein expression profiles can provide a very conclusive description 
of any given tumor entity, thereby selecting patients for targeted, individualized therapy. 
 
Conclusions 
In the scope of new targeted cancer therapy ap-
proaches new technologies which meet the issues of 
fast and precise target detection and quantification are 
desperately needed. RPPA is a very promising tool in 
t h i s   r e g a r d .   I t   h a s   a l r e a d y   b e e n   i m p l e m e n t e d   i n   s e v-
e r a l   b i o m a r k e r   s t u d i e s   a n d   b e c o m e s   e v e n   m o r e   p o-
w e r f u l   w h e n   c o m b i n e d   w i t h   t h e   h u g e   s a m p l e   r e s e r-
v o i r   p r o v i d e d   b y   F F P E   t i s s u e s .   I t   i s   c l e a r   n o w   t h a t  
proteins can b e   e x t r a c t e d   f r o m   F F P E   t i s s u e s   a n d   r e l i-
ably  analyzed.  We  believe  that  applying  these  new 
techniques - probably in conjunction with novel tissue 
fixatives -  w i l l   g r e a t l y   f a c i l i t a t e   t h e   s e a r c h   f o r   n e w  
biomarkers and therapeutic targets in the near future. 
More importantly, the great translational potential of 
the new approaches are apparent as the methodolo-
gies  discussed  can  easily  combine  classic  histopa-Journal of Cancer 2011, 2 
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thology  and  modern  multiplex  protein  profiling. 
However, in depth evaluation of antibodies and the 
use and design of proper controls for tissue quality 
are essential. 
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